# EDGAR Filing Document

**Accession Number:** 0000918294
**File Stem:** 0001999371-25-019951
**Filing Date:** 2025-12
**Character Count:** 4806
**Document Hash:** 240231452b64e8b40b8c255fbddbdf3b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-25-019951.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001999371-25-019951

**CONFORMED SUBMISSION TYPE**: 497

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**EFFECTIVENESS DATE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** T. Rowe Price Equity Series, Inc.
- **CENTRAL INDEX KEY:** 0000918294

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 497
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 033-52161
- **FILM NUMBER:** 251560894

**BUSINESS ADDRESS:**
- **STREET 1:** 1307 POINT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21231
- **BUSINESS PHONE:** 410-345-2000

**MAIL ADDRESS:**
- **STREET 1:** 1307 POINT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE EQUITY SERIES INC
- **DATE OF NAME CHANGE:** 19940131
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** T. Rowe Price Health Sciences Fund, Inc.
- **CENTRAL INDEX KEY:** 0001002624

**ORGANIZATION NAME:**
- **EIN:** 521952906
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 497
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 033-63759
- **FILM NUMBER:** 251560895

**BUSINESS ADDRESS:**
- **STREET 1:** 1307 POINT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21231
- **BUSINESS PHONE:** 410-345-2000

**MAIL ADDRESS:**
- **STREET 1:** 1307 POINT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE HEALTH SCIENCES FUND INC
- **DATE OF NAME CHANGE:** 19980513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE HEALTH & LIFE SCIENCES FUND INC
- **DATE OF NAME CHANGE:** 19951023

## Series and Classes Contracts Data

### T. Rowe Price Health Sciences Portfolio (Series ID: S000002083)

---

|  |  |  |
|:---|:---|:---|
| Class Name                                 | Ticker Symbol | Class ID   |
| T. Rowe Price Health Sciences Portfolio    | QAAGZX        | C000005448 |
| T. Rowe Price Health Sciences Portfolio-II | QAAHBX        | C000005449 |

---

### T. Rowe Price Health Sciences Fund, Inc. (Series ID: S000002088)

---

|  |  |  |
|:---|:---|:---|
| Class Name                                 | Ticker Symbol | Class ID   |
| T. Rowe Price Health Sciences Fund, Inc.   | PRHSX         | C000005456 |
| T. Rowe Price Health Sciences Fund-I Class | THISX         | C000169937 |

---

## Series and Classes Contracts Data

### T. Rowe Price Health Sciences Portfolio (Series ID: S000002083)

| Class ID   | Class Name                                 | Ticker Symbol   |
|:---|:---|:---|
| C000005448 | T. Rowe Price Health Sciences Portfolio    | QAAGZX          |
| C000005449 | T. Rowe Price Health Sciences Portfolio-II | QAAHBX          |

### T. Rowe Price Health Sciences Fund, Inc. (Series ID: S000002088)

| Class ID   | Class Name                                 | Ticker Symbol   |
|:---|:---|:---|
| C000005456 | T. Rowe Price Health Sciences Fund, Inc.   | PRHSX           |
| C000169937 | T. Rowe Price Health Sciences Fund-I Class | THISX           |

**T. Rowe Price Health Sciences Fund**

Supplement to Prospectus and Summary Prospectus dated March 1, 2025

------

**T. Rowe Price Health Sciences Portfolio**

Supplement to Prospectus and Summary Prospectus dated May 1, 2025

------

In the Summary Prospectus and Section 1 of the Prospectus, the disclosure under "Management" is supplemented as follows:

Effective April 1, 2026, Jeff Holford will join Ziad Bakri as the fund's co-portfolio manager and cochair of the fund's Investment Advisory Committee. On June 30, 2026, Mr. Bakri will step down from his role on the fund and, effective July 1, 2026, Mr. Holford will become the fund's sole portfolio manager and sole chair of the fund's Investment Advisory Committee. Mr. Holford joined T. Rowe Price in 2018.

In Section 2 of the Prospectus, the disclosure under "Portfolio Management" is supplemented as follows:

Effective April 1, 2026, Jeff Holford will join Ziad Bakri as the fund's co-portfolio manager and cochair of the fund's Investment Advisory Committee. On June 30, 2026, Mr. Bakri will step down from his role on the fund and, effective July 1, 2026, Mr. Holford will become the fund's sole portfolio manager and sole chair of the fund's Investment Advisory Committee. Mr. Holford joined the Firm in 2018, and his investment experience dates from 2001. During the past five years, he has served as an equity research analyst covering healthcare companies.

------

The date of this supplement is December 10, 2025.

------

G71-041 12/10/25